Development and Validation of an Enzyme Linked Immunosorbent Assay for Palivizumab Serum Determination

Abstract

Palivizumab (Synagis®) is a humanized monoclonal antibody (IgG1_K) composed of 95% human and 5% murine sequences. It is directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Palivizumab is used for prevention of serious lower respiratory tract disease caused by RSV in pediatric patients who are at increased risk of severe disease and is administered intramuscularly (IM) for a total of 5 monthly doses. Herein, we report on the development and validation of a very sensitive enzyme-linked immunosorbent assay (ELISA) to measure serum concentrations of palivizumab by a rabbit polyclonal antibody specifically produced against the murine sequence. The method was developed and validated according to the guidelines “Guidance for Industry” (1998) and has proved suitable for the determination of palivizumab serum levels in the target infant population. The ELISA assay was successfully applied to test the serum samples in an infant population who received palivizumab intramuscularly; thus, the assay could be used to determine serum levels in palivizumab-treated infants to optimize dosing and scheduling and to study the relationship between dose and clinical response.

Keywords

palivizumab Respiratory Syncytial Virus (RSV)ELISA infant patients

References

Murphy

Hall

Kulkarni

Crowe

Jr Collins

Connors

Karron

Chanock

. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994; 32(1):13–36.

Tempest

Bremner

Lambert

Taylor

Furze

JM.

Carr

. Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Nature Biothecnol 1991; 99:266–71.

Hall

Weinberg

Iwane

. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588–98.

Kim

Canchola

Brandt

Pyles

Chanock

Jensen

Parrott

, Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89(4):422–34.

Kapikian

Mitchell

Chanock

Shvedoff

Stewart

. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89(4):405–21.

The Impact-RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531–37.

Feltes

Cabalka

Meissnes

Piazza

Carlin

Top

FHJ

Connor

Sondheimer

. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532–40.

American Academy of Pediatrics, Committee on infectious disease and Committee on fetus and newborn. Prevention of respiratory syncytial virus infection: Indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics 1998; 102:1211–16.

American Academy of Pediatrics, Committee on infectious disease and Committee on fetus and newborn. Revised indication for the use of Palivizumab and respiratory syncytial virus immune globulin intravenous for prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1442–52.

10.

American Academy of Pediatrics, Committee on infectious disease and Committee on fetus and newborn. Policy statement – Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 112:1694–701.

11.

Subramanian

Weisman

Rhodes

. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to Respiratory Syncytial Virus in premature infants and infants with bronchopolmunary dysplasia. Pediatr Infect Dis J 1998; 17(2):110–15.

12.

Harlow

Lane

. Using Antibodies: A Laboratory Manual. CSHL Press. New York. USA, 1988.

13.

Laemmli

. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227:680.

14.

From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of Palivizumab for prevention of Respiratory Syncytial Virus infections. Pediatrics 2009; 124(6):1694–701.

15.

Johnson

Oliver

Prince

. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176(5):1215–24.

16.

Malley

De Vincenzo

Ramilo

. Reduction of Respiratory Syncytial Virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998; 178:1555–61.

17.

Llorens

Moreno

Ramilo

Sanchez

Top

FHJ

Connor

. Safety and pharmacokinetics of Palivizumab therapy in children hospitalized with Respiratory Syncytial Virus infection. Pediatr Infect Dis J 2004; 23:707–12

18.

Llorens

Castano

Null

Steichen

Sanchez

Ramilo

Por

Jr Connor

. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to Respiratory Syncytial Virus in premature infants and infants with bronchopolmunary dysplasia. Pediatr Infect Dis J 1998; 17(9):787–91.